Aug 2026· Pathology international (Print)· Vol 76· 0 citations· 21 references
Medicine
TL;DR
It is illustrated that concordant mismatch repair protein loss across multiple tumors provides compelling morphological evidence to guide pathologists in reconsidering negative panel results and pursuing comprehensive genomic investigation to identify pathogenic intronic variants.
Abstract
Tumors exhibiting mismatch repair deficiency without detectable germline mutations via standard multigene panel testing are often classified as Lynch‐like syndrome. In the present report, we describe the case of a 47‐year‐old man presenting with synchronous axillary sebaceous carcinoma and colonic medullary carcinoma. Although initial germline multigene panel testing failed to identify pathogenic variants, a high degree of pathological suspicion for Muir–Torre syndrome remained. Immunohistochemistry revealed a concordant loss of MSH2 and MSH6 expression in both the extraocular sebaceous carcinoma and the colonic medullary carcinoma. This identical protein‐loss pattern detected across anatomically distinct tumors served as decisive pathological evidence of an underlying germline defect rather than independent biallelic somatic mutations. Consequently, whole‐genome sequencing was performed to resolve the discrepancy between the pathological findings and multigene panel testing results, successfully identifying a germline intronic MSH2 variant (NM_000251.3:c.2459‐12A>G). Subsequent RNA analysis confirmed aberrant splicing with an 11‐bp insertion. In conclusion, the present case illustrates that concordant mismatch repair protein loss across multiple tumors provides compelling morphological evidence to guide pathologists in reconsidering negative panel results and pursuing comprehensive genomic investigation to identify pathogenic intronic variants.
This case highlights that preserved tumor MMR immunostaining does not exclude Lynch syndrome when clinical suspicion is high and Concurrent MSI and MMR immunohistochemistry, interpreted together with tumor sequencing and germline testing, may improve diagnosis, treatment selection, and familial risk assessment.
Jing-Jing Cai, Zhuo-Ying Li, Ting-Ting Han et al.· Clinical Case Reports· 0 citations
A male infant with a severe FINCA-like phenotype is reported, including early-onset hemolytic anemia, pulmonary involvement, neurodevelopmental impairment, growth failure, recurrent infections, and fatal progression at 8.5 months.
A. Rozhkova, Anton A. Esibov, Aleksandra Borkovskaia et al.· International Journal of Mol...· 0 citations
This case highlights the co-occurrence of an NF1 variant and dMMR colorectal cancer and underscores the need for further studies to determine whether this represents a coincidental finding or a biologically meaningful association.
Feras Alsabagh, Karam M. Chaaban, M. Girardo et al.· Exploration of neuroscience· 0 citations
Germline predisposition syndromes are increasingly recognized in young patients presenting with myelodysplastic syndromes (MDS) and bone marrow failure. Among these, GATA2 deficiency represents a well-established cause of hereditary susceptibility to myeloid malignancies, whereas constitutional STAG2 alterations are ra...
Onda-Tabita Călugăru, D. Coriu, C. Jardan et al.· Frontiers in Medicine· 0 citations
A Chinese patient presenting with classic hallmarks of MGORS7 alongside atypical clinical features, including hearing and visual impairments is reported, suggesting that growth hormone therapy may be beneficial for growth retardation in patients with MGORS7.
Ying Zhao, Yi-Yang Fu, Shu-Ying Zhang et al.· Frontiers in Genetics· 0 citations
A comparison of all reported ZKS patients suggests that this syndrome displays a recognizable pattern of developmental delay, intellectual disability, postnatal microcephaly, facial dysmorphism, skeletal and ocular anomalies, and short stature.
Naeim Ehtesham, M. Mazaheri, Z. Sadr et al.· European Journal of Medical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.